100% FREE Shipping on all orders

tetrava labs website logo
Buy cagrilintide semaglutide blend for sale in research vials
Download COA (PDF)

Batch A001 · 5mg · 99.00% purity · +1 more lot

Cagrilintide + Semaglutide (5mg)

For Research Use Only. Not for human consumption.

99%+ purity

$89.00 – $712.00

Buy Cagrilintide + Semaglutide online from Tetrava Labs. This cagrilintide + semaglutide research blend pairs an amylin analogue with a GLP-1 receptor agonist for dual-incretin pathway studies.

  • FREE shipping on all orders
  • Guaranteed delivery to your doorstep
  • Secure payment with card or crypto
  • Enjoy discounts with every purchase

24/7 support — Email or WhatsApp

Select strength

Choose pack size

1 / 5 / 10 vials

$712.00

$890.00

10 vials · $71.20/vial

You save $178

HPLC VerifiedCold ShipCOA Included

Cagrilintide + Semaglutide Peptide

The cagrilintide + semaglutide blend is two ligands in one research vial: cagrilintide (AM833), a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist.[1]

Tetrava Labs sells this cagrilintide-semaglutide blend as a lyophilized research peptides reagent for dual-pathway metabolic assays, not as CagriSema and not as a branded pen. Research use only. Not for human or veterinary consumption.

Specifications

These fields are the catalog identity for Cagrilintide + Semaglutide. Match the lot on the vial to the COA library published by Tetrava Labs before an assay. CAS 1415456-99-3 is the registry lookup on PubChem.

CAS Number1415456-99-3
Molecular FormulaC194H312N54O59 | C187H291N45O59
Molecular WeightSee component peptides
SequenceMulti-component: see Cagrilintide and Semaglutide
Other Known TitlesCagriSema (investigational name, not this SKU), AM833 + semaglutide, Cagrilintide/semaglutide blend, Cagrilintide-semaglutide research blend

Cagrilintide + Semaglutide Research

Mechanism

Cagrilintide is an amylin analogue. It is not a GLP-1 agonist. Semaglutide is the GLP-1 agonist in the pair.[1] A cagrilintide semaglutide vial therefore asks an amylin-plus-GLP-1 question with two molecules, two receptor families.

That is a different design from a single-chain dual agonist. If the protocol needs amylin-receptor pharmacology next to GLP-1-receptor pharmacology, the blend is a convenience lot. If the protocol needs one molecule that hits GIP and GLP-1, it is the wrong vial.

Scientist comparing a cagrilintide semaglutide dual-vial layout with amylin and GLP-1 receptor diagrams

What the published models measured

Is cagrilintide a GLP? No. Cagrilintide is an amylin analogue. Semaglutide is the GLP-1 component. Calling the blend a GLP erases half the mechanism.

Is cagrilintide FDA approved? Also no. CagriSema is an investigational Novo combination name, not an approved finished drug, and not this catalog blend. Ozempic is a branded semaglutide product. Two powders in one RUO vial are not a pen, and they are not tirzepatide, which is one GIP/GLP-1 molecule.

Enebo, Berthelsen, Kankam, and colleagues ran a randomised, controlled phase 1b trial of multiple doses of cagrilintide given with semaglutide 2.4 mg, reading safety, tolerability, pharmacokinetics, and pharmacodynamics.[1] That paper is about concomitant administration of two defined clinical-program materials, not about an unlabeled research blend.

Use it to justify a combination-pharmacology question: amylin analogue plus GLP-1 agonist in the same protocol. Do not copy the trial's product, device, or escalation schema onto this SKU. Later CagriSema programs sit outside this page unless a lot-linked paper is in the reference list.

Cagrilintide vs semaglutide is an amylin-receptor question versus a GLP-1-receptor question. The blend holds both ligands. Cagrilintide vs tirzepatide is a worse mix-up: tirzepatide is a single GIP/GLP-1 dual agonist, not an amylin analogue and not a two-vial combination.[1]

Pick the arm from the receptor list. Amylin plus GLP-1: this blend. GLP-1 only: standalone semaglutide. GIP plus GLP-1 in one chain: tirzepatide. Do not treat those three as interchangeable metabolic reagents.

Buy Cagrilintide + Semaglutide online. Two researchers reviewing cagrilintide vs tirzepatide pathway cards beside the blend research vials

Where the evidence stops

Research-use-only material is not a prescription, a compounded drug, or a personal-use protocol. A paper or an approved label describes its own method. It does not describe this vial.

Gloved hand aligning a cagrilintide-semaglutide blend COA with both lyophilized vials

Identity and the certificate of analysis

A cagrilintide-semaglutide blend needs two identities on one chromatogram. One purity number for the vial is not enough if the method cannot resolve both peaks. Tetrava lists 5 mg and 10 mg blend vials.

Confirm cagrilintide and semaglutide on the same lot Certificate of Analysis. Lot on the vial matches lot on the PDF. No CagriSema, Ozempic, or tirzepatide branding on an RUO blend.

The blend ships lyophilized. Store sealed vials at -20 C. Log both identities, the diluent lot, concentration, date, and operator against the batch COA.

References

  1. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748.

Author Profile

Tetrava Labs Editorial Team

Tetrava Labs Editorial Team

Editorial Team, Tetrava Labs

Content published by Tetrava Labs is compiled and fact-checked using peer-reviewed scientific literature, HPLC-MS Certificates of Analysis (COA), and primary biochemical data. Research use only.

Frequently Asked Questions

Research Use Only Disclaimer

All products are intended for laboratory research purposes only. Not approved for human consumption, diagnostic use, or therapeutic applications. By purchasing, you confirm you are a qualified research professional.

You may also like